Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2014

Open Access 01-12-2014 | Research

Association between circulating adiponectin levels and polycystic ovarian syndrome

Authors: Saira Saeed Mirza, Kashif Shafique, Abdul Rauf Shaikh, Naveed Ali Khan, Masood Anwar Qureshi

Published in: Journal of Ovarian Research | Issue 1/2014

Login to get access

Abstract

Background

Low adiponectin levels in polycystic ovarian syndrome (PCOS) have been largely attributed to obesity which is common among these patients. In addition, evidence also suggests that low adiponectin in PCOS may be related to insulin resistance (IR) in these women. However, studies on the role of adiponectin in younger and lean patients are limited. Therefore, the aim of the present study was to examine the association of adiponectin levels in young and lean women with PCOS.

Methods

A case–control study was conducted at the Dow University of Health Sciences, Karachi, Pakistan. Cases were 75 patients of PCOS with Body Mass Index (BMI) &23 aged 16–35 years and 75 healthy age and BMI matched controls were selected from family and friends of the cases. Demographic details, family history and past medical history were obtained through interview by a physician. Anthropometric measurements included weight and height of the participants. Fasting glucose, total cholesterol, high-density lipoprotein (HDL), insulin, adiponectin, and androgen levels were determined. IR was calculated using homeostasis model assessment for insulin resistance (HOMA-IR). Logistic regression models were used to assess the association between adiponectin and PCOS after adjusting for co-variates.

Results

On multivariable analysis, PCOS cases were 3.2 times more likely to have low adiponectin level (OR = 3.2, 95% CI 1.49-6.90, p-value 0.003) compared to the controls after adjustment for age, BMI, family history, marital status, total cholesterol, HDL level and IR. Females with a family history of PCOS were significantly more likely to have lower adiponectin (OR = 3.32, 95% CI 1.27-8.67, p-value 0.014) compared to those who did not have a family history of PCOS. The associations of IR and family history with low adiponectin level also remained statistically significant after adjustments for covariates.

Conclusion

Serum adiponectin levels are independently associated with PCOS and are only partly explained by IR. Adiponectin level may serve as a potential independent biomarker for diagnosis of PCOS in young and lean women with fewer symptoms, or women with a family history of PCOS.
Appendix
Available only for authorised users
Literature
1.
Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, et al.: Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009, 15: 297–307. 10.1093/humupd/dmp006CrossRefPubMed
2.
Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol 1961, 21: 1440–1447. 10.1210/jcem-21-11-1440CrossRef
3.
Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A: Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007, 88: 1389–1395. 10.1016/j.fertnstert.2007.01.032CrossRefPubMed
4.
Cho LW, Randeva HS, Atkin SL: Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag 2007, 3: 55–63.PubMedCentralPubMed
5.
Handelsman Y: Metabolic syndrome pathophysiology and clinical presentation. Toxicol Pathol 2009, 37: 18–20. 10.1177/0192623308329288CrossRefPubMed
6.
7.
Katulski K, Meczekalski B: Natural history of polycyclic ovary syndrome. Pol Merkur Lekarski 2010, 29: 58–60.PubMed
8.
Liu X, Zhang J, Li Y, Xu L, Wei D, Qiu D, et al.: On the relationship between serum total adiponectin and insulin resistance in polycystic ovary syndrome. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2010, 27: 636–640.PubMed
9.
Vrbikova J, Dvorakova K, Hill M, Vcelak J, Stanicka S, Vankova M, et al.: Determinants of circulating adiponectin in women with polycystic ovary syndrome. Gynecol Obstet Invest 2005, 60: 155–161. 10.1159/000086273CrossRefPubMed
10.
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7: 941–946. 10.1038/90984CrossRefPubMed
11.
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86: 1930–1935. 10.1210/jcem.86.5.7463CrossRefPubMed
12.
Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR: Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril 2008, 89: 1200–1208. 10.1016/j.fertnstert.2007.04.046CrossRefPubMed
13.
Azziz R: Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006, 91: 781–785. 10.1210/jc.2005-2153CrossRefPubMed
14.
World Health Organization-International Obesity Task Force: The Asia-pacific perspective: redefining obesity and its treatment. Health communications Australia. 2000.
15.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovarian syndrome. Fertil Steril 2004, 81: 19–25.
16.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–419. 10.1007/BF00280883CrossRefPubMed
17.
Harrison S, Somani N, Bergfeld WF: Update on the management of hirsutism. Cleve Clin J Med 2010, 77: 388–98. 10.3949/ccjm.77a.08079CrossRefPubMed
18.
Ardawi MS, Rouzi AA: Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2005, 83: 1708–1716. 10.1016/j.fertnstert.2004.11.077CrossRefPubMed
19.
Barber TM, Hazell M, Christodoulides C, Golding SJ, Alvey C, Burling K, et al.: Serum levels of retinol-binding protein 4 and adiponectin in women with polycystic ovary syndrome: associations with visceral fat but no evidence for fat mass-independent effects on pathogenesis in this condition. J Clin Endocrinol Metab 2008, 93: 2859–2865. 10.1210/jc.2007-2759CrossRefPubMed
20.
Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, et al.: Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005, 152: 389–394. 10.1530/eje.1.01868CrossRefPubMed
21.
Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchon R, Luque-Ramirez M, et al.: Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 2006, 21: 2257–2265. 10.1093/humrep/del146CrossRefPubMed
22.
Sepilian V, Nagamani M: Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance. J Soc Gynecol Investig 2005, 12: 129–134. 10.1016/j.jsgi.2004.09.003CrossRefPubMed
23.
Wickham EP III, Cheang KI, Clore JN, Baillargeon JP, Nestler JE: Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome. Metabolism 2011, 60: 366–72. 10.1016/j.metabol.2010.02.019PubMedCentralCrossRefPubMed
24.
Weyer C, Tataranni PA, Bogardus C, Pratley RE: Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001, 24: 89–94. 10.2337/diacare.24.1.89CrossRefPubMed
25.
Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, et al.: Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010, 95: 722–730. 10.1210/jc.2009-1985CrossRefPubMed
26.
Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R: Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008, 93: 2670–2678. 10.1210/jc.2008-0115CrossRefPubMed
27.
Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, et al.: Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 2007, 156: 263–269. 10.1530/eje.1.02331CrossRefPubMed
28.
Glintborg D, Frystyk J, Hojlund K, Andersen KK, Henriksen JE, Hermann AP, et al.: Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008, 68: 165–174.
29.
Rodin DA, Bano G, Bland JM, Taylor K, Nussey SS: Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 1998, 49: 91–99. 10.1046/j.1365-2265.1998.00492.xCrossRef
30.
Crosignani PG, Nicolosi AE: Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod Update 2001, 7: 3–7. 10.1093/humupd/7.1.3CrossRefPubMed
31.
Sir-Petermann T, Maliqueo M, Codner E, Echiburu B, Crisosto N, Perez V, et al.: Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92: 4637–4642. 10.1210/jc.2007-1036CrossRefPubMed
Metadata
Title
Association between circulating adiponectin levels and polycystic ovarian syndrome
Authors
Saira Saeed Mirza
Kashif Shafique
Abdul Rauf Shaikh
Naveed Ali Khan
Masood Anwar Qureshi
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2014
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/1757-2215-7-18

Other articles of this Issue 1/2014

Journal of Ovarian Research 1/2014 Go to the issue

Research

Increased expression of the leptin receptor in human ovaries affected by endometrioma and detection of high levels of leptin in the ovarian endometriomal fluid

Case report

Ovarian cancer initially presenting with isolated ipsilateral superficial inguinal lymph node metastasis: a case study and review of the literature

Research

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

Research

Epicardial adipose tissue thickness and NGAL levels in women with polycystic ovary syndrome

Review

Notch signaling in serous ovarian cancer

Research

Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids